Low-dose Atropine for the Prevention of Myopia Progression in Danish Children
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Myopia
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 6 years and 12 years
- Gender
- Both males and females
Description
The main hypotheses tested in this study are: 0.01% atropine one drop nightly reduces the progression of childhood myopia in Danish children. 0.01% atropine one drop nightly is safe and with no significant side effects. A 6-month loading dose of 0.1% atropine followed by a 0.01% atropine maintenance...
The main hypotheses tested in this study are: 0.01% atropine one drop nightly reduces the progression of childhood myopia in Danish children. 0.01% atropine one drop nightly is safe and with no significant side effects. A 6-month loading dose of 0.1% atropine followed by a 0.01% atropine maintenance dose is superior to single 0.01% atropine. 0.1% atropine one drop nightly is safe and has tolerable side effects. The rebound effect after stopping both atropine regimens is limited. Choroidal thickness is a predictor for the progression of childhood myopia.
Tracking Information
- NCT #
- NCT03911271
- Collaborators
- Aarhus University Hospital
- Vejle Hospital
- Investigators
- Not Provided
Get Well Soon